Diagnostik bei Myalgien

C. Berghoff; A. Bayas; R. Gold; C. Sommer; D. Pongratz; D. Heuss

doi:10.1055/s-0038-1630002

Nervenheilkunde, Table of Contents

Nervenheilkunde 2005; 24(08): 702-708
DOI: 10.1055/s-0038-1630002

Deutsche Gesellschaft für Muskelkranke e.V.

Schattauer GmbH

Diagnostik bei Myalgien

Bundeseinheitliche Konsensuspapiere der Neuromuskulären Zentren im Auftrag der Deutschen Gesellschaft für Muskelkranke e.V. (DGM)Myalgias diagnosticsconsensus statement of the German Centers for Neuromuscular Disease

Authors

C. Berghoff

¹Neurologische Klinik der Universität Erlangen-Nürnberg
A. Bayas

²Neurologische Klinik der Universität Würzburg
R. Gold

³Institut für MS-Forschung, Bereich Humanmedizin der Universität Göttingen und Gemeinnützige Hertie-Stiftung
C. Sommer

²Neurologische Klinik der Universität Würzburg
D. Pongratz

⁴Friedrich-Baur-Institut München
D. Heuss

¹Neurologische Klinik der Universität Erlangen-Nürnberg

Abstract

Zusammenfassung

Lokalisierte oder generalisierte Schmerzen der Skelettmuskulatur sind häufige Leit- oder Begleitsymptome von Erkrankungen aus verschiedenen medizinischen Fachdisziplinen. Die ätiologische Abklärung von Myalgien erfolgt anhand des Beschwerdebildes, des klinischen Untersuchungsbefundes und gegebenenfalls weiterführender Untersuchungen. Die vorliegende Arbeit stellt alle derzeitigen diagnostischen Möglichkeiten vor sowie einen Algorithmus für die zielgerichtete Diagnostik bei Myalgien.

Summary

Localized or generalized muscle pain is a common symptom associated with a variety of neurological and other diseases. The etiologic differentiation of myalgias is based on history and clinical findings and may include further diagnostic investigations. Here we present current diagnostic possibilities including an algorithm for an efficient approach to the diagnosis of myalgias.

Schlüsselwörter

Myalgie - Muskelschmerz - Diagnostik

Keywords

Myalgia - muscle pain - diagnostic investigation

Full Text

References

Literatur
1 Späth M. Aktuelles zu Diagnostik und Therapie bei Myalgien ohne definierte Myopathie. Nervenheilkunde 2002; 21: 29-34.
2 Gempel K. et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 2002; 25: 17-27.
3 Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7: 560-7.
4 Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27: 142-56.
5 Pongratz D, Müller-Felber W. Muskelschmerzen. Internist (Berl) 1990; 31: 41-50.
6 Mense S. Neurobiologische Grundlagen von Muskelschmerz. Schmerz 1999; 13: 3-17.
7 Franz M, Mense S. Muscle receptors with group IV afferent fibres responding to application of bradykinin. Brain Res 1975; 92: 369-83.
8 Babenko V. et al. Experimental human muscle pain and muscular hyperalgesia induced by combinations of serotonin and bradykinin. Pain 1999; 82: 1-8.
9 Ernberg M. et al. The level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci 1999; 65: 313-25.
10 Issberner U, Reeh PW, Stehen KH. Pain due to tissue acidosis: a mechanism for inflammatory and ischemic myalgia?. Neurosci Let 1996; 208: 191-4.
11 Hedenberg-Magnusson B. et al. Pain mediation by prostaglandin E2 and leukotriene B4 in the human masseter muscle. Acta Odontol Scand 2001; 59: 348-55.
12 Schäfers M, Sorkin LS, Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 2003; 104: 579-88.
13 Pongratz D, Späth M. Fibromyalgie. Fortschr Neurol Psychiatr 2001; 69: 189-93.
14 Vaerøy H. et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-6.
15 Russell IJ. et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593-601.
16 Maes M. et al. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 1999; 24: 371-83.
17 Wallace DJ. et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001; 40: 743-9.
18 Gur A. et al. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002; 20: 753-60.
19 Salemi S. et al. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003; 30: 146-50.
20 Bayas A, Gold R. Diagnostische Prinzipien bei Muskelerkrankungen. Fortschr Neurol Psychiatr 2003; 71: 61-6.
21 Timpl P. et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19: 162-6.
22 Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1: 277-99.
23 Stein C, Mendl G. The German counterpart to McGill Pain Questionnaire. Pain 1988; 32: 251-5.
24 George A. et al. Musculosceletal pain in myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-42.
25 Bohner J. et al. Stability of macro creatine kinases and creatine kinase isoenzymes compared: heat inactivation test for determination of thermostable creatine kinases. J Clin Chem Clin Biochem 1981; 19: 1021-6.
26 Pointner H. Enzymaktivitäten im Plasma. In: Laboratoriumsdiagnostik. G.G.; Deutsch E, Wenger R. (Ed). Medizinisch wissenschaftliche Buchreihe von Schering. 1992: 781-3.
27 Lindner A, Zierz S. Rhabdomyolyse und Myoglobinurie. Nervenarzt 2003; 74: 505-15.
28 Lindner A. et al. Acute compartment syndrome after forearm ischemic work test in a patient with McArdle’s disease. Neurology 2001; 56: 1779-80.
29 Hogrel JY. et al. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001; 56: 1733-8.
30 Kazemi-Esfarjani P. et al. A non-ischemic forearm exercise test for McArdle disease. Ann Neurol 2002; 52: 153-9.
31 Heuss D. Muskelschmerzen. Nervenheilkunde 1998; 17: 201-6.
32 Heuss D, Claus D, Neundörfer B. Fibrillations in regenerating muscle in dystrophic myopathies. Clin Neuropathol 1996; 15: 200-8.
33 Lofberg M. et al. Antimyosin scintigraphy compared with magnetic resonance imaging in inflammatory myopathies. Arch Neurol 1998; 55: 987-93.
34 Reimers CD, Kele H. Muskelsonographie bei neuromuskulären Erkrankungen. Orthopäde 2002; 31: 165-71.
35 Mastaglia FL. et al. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27: 407-25.
36 Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep 2001; 3: 334-45.
37 Beggs AH. et al. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 1990; 86: 45-8.
38 Mendell JR. et al. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 2001; 57: 645-50.
39 Niiyama T. et al. Diagnosis of dystrophinopathy by skin biopsy. Muscle Nerve 2002; 25: 398-401.
40 Mills KR, Edwards RH. Investigative strategies for muscle pain. J Neurol Sci 1983; 58: 73-8.